NCT07842484

Brief Summary

Muscle activity in the upper airway is influenced by specific states such as anesthesia, sleep, wakefulness, and the phases of respiration. The hypoglossal nerve, which innervates the genioglossus muscle, receives input from the brain's sleep-wake center, respiratory pattern-generating neurons, chemoreceptors, and airway negative pressure receptors. Preliminary activation of the genioglossus muscle and other upper airway dilators by the hypoglossal nerve occurs approximately 50-200 ms before innervation of the phrenic motor neurons and the subsequent action of the diaphragm. The forward movement of the genioglossus increases the stiffness and diameter of the upper airway, effectively counteracting collapse forces during inspiration. Assessing genioglossus function could prove critical in determining the optimal timing for extubation. This requires a methodology to evaluate the upper airway by measuring genioglossus activity in intubated patients. In the future, this could provide an objective measure for assessing suitability for extubation. This study explores a method for measuring the electrical activity of the upper airway muscles and the diaphragm in ventilated patients and correlates the results in a systematic view.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
5mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Sep 2026Mar 2027

Study Start

First participant enrolled

September 1, 2026

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2026

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 25, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

September 25, 2026

Status Verified

September 1, 2026

Enrollment Period

6 months

First QC Date

September 9, 2026

Last Update Submit

September 21, 2026

Conditions

Keywords

genioglossus (GG) muscle activitynon-invasive EMG

Outcome Measures

Primary Outcomes (1)

  • Proportion (with 95% confidence intervals) of participants meeting the stimulation success criterion.

    Proportion (with 95% confidence intervals) of participants meeting the stimulation success criterion.

    6 months

Secondary Outcomes (4)

  • Proportion completing each measurement (Baseline - initial, Challenge, Baseline - subsequent).

    6 months

  • Change in GG-EMG amplitude from baseline to physiological challenge quantified as RMS or peak-to-peak

    between Day 1 and Day 3 recordings

  • Change in GG-EMG amplitude between Day 1 and Day 3 recordings

    1-3 days

  • Correlation of EMG metrics and clinical variables (e.g., sedation depth, PCO₂, neurological status)

    6 months

Study Arms (1)

patients dependent on invasive mechanical ventilation and extubation

EXPERIMENTAL
Procedure: electromyography (EMG) of genioglossus (GG)

Interventions

Measurement of efferent neural drive from respiratory centers to upper airways using electromyography (EMG) of genioglossus (GG) in patients dependent on invasive mechanical ventilation

patients dependent on invasive mechanical ventilation and extubation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older.
  • Dependent on invasive mechanical ventilation in ICU
  • Awakening patient: improving neurological status (+2 points on the GCS compared to admission)
  • Patient weaning from mechanical ventilation: presence of ventilator-recorded weaning trigger.

You may not qualify if:

  • Known pregnancy
  • Unstable intracranial pressure
  • Pacemaker, internal defibrillator or pacing device wearers.
  • Aneurysms at risk of rupture
  • Severely impaired gas exchange despite optimal therapy
  • GCS \< 5 or clinical signs of poor prognosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Lombardy, 27100, Italy

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 9, 2026

First Posted

September 25, 2026

Study Start

September 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Last Updated

September 25, 2026

Record last verified: 2026-09

Locations